•  Summary 
  •  
  •  Actions 
  •  
  •  Committee Votes 
  •  
  •  Floor Votes 
  •  
  •  Memo 
  •  
  •  Text 
  •  
  •  LFIN 
  •  
  •  Chamber Video/Transcript 

AB9552 Text:



 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                         9552--C
 
                   IN ASSEMBLY
 
                                    January 23, 2018
                                       ___________
 
        Introduced  by  M.  of  A. L. ROSENTHAL -- read once and referred to the
          Committee on Social Services -- committee  discharged,  bill  amended,
          ordered  reprinted  as  amended  and  recommitted to said committee --
          again reported from said committee with amendments, ordered  reprinted
          as  amended and recommitted to said committee -- reported and referred
          to the Committee on  Codes  --  committee  discharged,  bill  amended,
          ordered reprinted as amended and recommitted to said committee
 
        AN  ACT to amend the social services law, in relation to requiring home-
          less shelters to keep an opioid antagonist on hand, have at least  one
          trained  employee  on  duty at all times, and provide an opioid antag-
          onist training program for residents
 
          The People of the State of New York, represented in Senate and  Assem-
        bly, do enact as follows:
 
     1    Section 1. Article 2-A of the social services law is amended by adding
     2  a new title 3 to read as follows:
     3                                   TITLE 3
     4                   OPIOID ANTAGONISTS IN HOMELESS SHELTERS
     5  Section 47. Opioid antagonist use and training.
     6    § 47. Opioid antagonist use and training. 1. Any provider of temporary
     7  housing assistance, which shall include, but not be limited to, a family
     8  shelter, a shelter for adults, a hotel, an emergency apartment, a domes-
     9  tic  violence  shelter,  a runaway and homeless youth shelter, or a safe
    10  house for refugees operating in this state shall have at its premises at
    11  all times:
    12    (a) an opioid antagonist and a method  of  administering  it  on  site
    13  which may include, but not be limited to, a naloxone kit; and
    14    (b)  at  a  minimum,  one employee trained in the administration of an
    15  opioid antagonist on duty at all times.
    16    2. All employees of providers of temporary public  housing  assistance
    17  who are authorized to administer an opioid antagonist shall:
    18    (a)  have  completed  an initial training program, which may include a
    19  department of health  registered  opioid  overdose  prevention  training
    20  program;
    21    (b) complete a refresher training program at least every two years;
 
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD13741-05-8

        A. 9552--C                          2
 
     1    (c)  contact  the  emergency  medical  system during any response to a
     2  victim of suspected drug overdose and advise if an opioid antagonist  is
     3  being used;
     4    (d)  comply  with  protocols for response to victims of suspected drug
     5  overdose; and
     6    (e) report all responses to victims of suspected drug overdose to  the
     7  department of health.
     8    3.  All  providers  of  temporary  housing  assistance shall develop a
     9  training  plan  in  conjunction  with  a  registered   opioid   overdose
    10  prevention program in the applicable region regarding the administration
    11  of  opioid  antagonists to any individual residing on a provider's prem-
    12  ises who is at risk of experiencing or witnessing an opioid overdose.
    13    4. For the purposes of this subdivision, the term "opioid  antagonist"
    14  shall  mean  a  federal food and drug administration-approved drug that,
    15  when administered, negates or neutralizes in whole or in part the  phar-
    16  macological  effects  of  an  opioid  in the body and that is limited to
    17  naloxone or other medications approved by the department of  health  for
    18  this  purpose and "naloxone kit" shall mean a prefilled naloxone syringe
    19  or needle-free intranasal drug delivery device.
    20    5. The commissioner is authorized to promulgate rules and  regulations
    21  necessary for the implementation of this title.
    22    §  2.  This  act shall take effect on the thirtieth day after it shall
    23  have become a law. Effective immediately, the addition, amendment and/or
    24  repeal of any rule or regulation necessary  for  the  implementation  of
    25  this  act  on its effective date are authorized to be made and completed
    26  on or before such effective date.
Go to top